Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing
13 févr. 2024 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla. and LELAND, N.C., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Dyadic International Inc. (“Dyadic”, or the “Company”) (Nasdaq: DYAI) and Cygnus Technologies®, part of Maravai LifeSciences®...
Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company
06 févr. 2024 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company announced it has signed a...
Albumin Market revenue to cross USD 10 Billion by 2035, says Research Nester
02 oct. 2023 06h30 HE
|
Research Nester
New York, Oct. 02, 2023 (GLOBE NEWSWIRE) -- The global albumin market size is slated to expand at ~ 6% CAGR between 2023 and 2035. The market is poised to garner a revenue of USD 10 Billion by the...
Dyadic Announces Development and License Agreement to Commercialize Animal-Free Alternative Proteins Using Dapibus™
19 sept. 2023 08h00 HE
|
Dyadic International, Inc.
Dyadic to receive upfront payment of $0.6 million for product development and licensing its Dapibus™ platform, in addition to potential success fees, milestones, and royalties. JUPITER, Fla., Sept. ...
[Latest] Global Recombinant Human Insulin Market Size/Share Worth USD 55.99 Billion by 2032 at a 8.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
25 août 2023 16h30 HE
|
Custom Market Insights
Austin, TX, USA, Aug. 26, 2023 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Recombinant Human Insulin Market Size, Trends and Insights By Product (Regular...
Dyadic Announces Continued Progress Towards Commercialization of Animal-Free Recombinant Serum Albumin
07 août 2023 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Human Serum Albumin (HSA) Market to Garner $7,124.9 Million by 2031 with 6.8% CAGR | Research Dive
19 juin 2023 09h05 HE
|
Research Dive
New York, USA, June 19, 2023 (GLOBE NEWSWIRE) -- According to Research Dive’s newly published report, the global human serum albumin (HSA) market is predicted to grow at a stable CAGR of 6.8%,...
Dyadic Announces Initiation of Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
24 janv. 2023 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Business Expansion: Global Albumin Market Estimated to Generate a Revenue of $8,129.1 Million and Grow at 10.1% CAGR in the 2021-2028 Timeframe [175-Pages] | Confirmed By Research Dive
27 avr. 2022 09h15 HE
|
Research Dive
New York, USA, April 27, 2022 (GLOBE NEWSWIRE) -- According to the report published by Research Dive, the global albumin market is estimated to garner a revenue of $8,129.1 million by 2028 and grow...
Vaccines Market revenue to cross USD 83.5 Bn by 2027: Global Market Insights Inc.
03 juin 2021 02h00 HE
|
Global Market Insights, Inc
Selbyville, Delaware, June 03, 2021 (GLOBE NEWSWIRE) -- According to latest report “Vaccines Market by Age Group (Pediatric, Adult), Disease (Cancer, Hepatitis, Pneumococcal Disease, DTP, Dengue,...